AMANTANSEAmanta Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 11 Nov, 2025 · 17:39 IST

Amanta Healthcare Q2 FY26 PAT up 31% YoY at Rs 282.70 lakh

Exceptional ItemPat Growth 25pctResults View source PDFExplain this filing

AMANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.0%Reaction day
₹122.84
prior close
₹121.35
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-1.9% vs market
Pharmaceuticals peers, median of 157sector+0.8%-1.8% vs sector

On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.5
10m
+0.8
15m
+0.8
30m
+0.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.0+0.9-1.9+0.8-1.8
Next day
-3.1+0.8-4.0+0.5-3.6
2d
-1.5+0.7-2.2+0.4-1.9
3d
+0.1+1.3-1.2+0.6-0.4
4d
-2.9+0.5-3.5-0.1-2.8
5d
-5.6+0.4-5.9-0.6-5.0
1w
-4.8-1.5-3.3-1.2-3.6
15d
-15.5-2.4-13.1-1.8-13.7
1m
-14.3-4.4-9.9-2.6-11.7
2m
-9.8-7.2-2.6-5.4-4.5
3m
-11.4-5.0-6.4-5.7-5.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 and H1 FY26 results for period ended Sept 30, 2025. Q2 revenue Rs 7,088.73 lakh, up 6% YoY. Q2 PAT Rs 282.70 lakh, up 31% YoY. H1 FY26 revenue Rs 13,619.41 lakh vs Rs 13,483.1 lakh YoY. H1 PAT Rs 733.36 lakh vs Rs 471.47 lakh YoY, a 56% jump. Exceptional item of Rs 262.88 lakh booked for listing-related share issue expenses. Price Waterhouse gave an unmodified review opinion.

Likely market impact

Strong PAT growth despite modest revenue. Exceptional item is non-cash share listing cost. First results as listed company.